- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07584343
EMG of Gait Under Dual-Task in Parkinson Desease (EMG-DT-PD)
Electromyographic Activity of the Tibialis Anterior and Medial Gastrocnemius in Parkinson's Disease During Forward and Backward Gait Under Dual-Tasking: A Descriptive Study
In this observational study embedded within a randomized controlled trial, the investigators aim to characterize the activation patterns of the tibialis anterior and medial gastrocnemius muscles in the more rigid leg of patients with Parkinson's disease when performing walking tasks under dual cognitive-task conditions, which are known to increase the risk of falls in this population.
To this end, a control group without neurological disorders and with comparable sociodemographic characteristics will also be assessed.
The study seeks to determine whether significant changes occur in forward and backward gait as a function of the dual-task condition.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Sevilla
-
Seville, Sevilla, Spanien, 41015
- Sevilla, España
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Ability to walk independently for at least 5 meters, both forward and backward, without the need for assistive devices or assistance from another person.
- Diagnosis of idiopathic Parkinson's disease made by a neurologist at Hospital Virgen Macarena.
- Hoehn and Yahr stage I-III.
- Being in the "ON" phase of antiparkinsonian medication during the assessment (approximately one hour after intake, when the pharmacokinetic curve of levodopa reaches its peak).
Exclusion Criteria:
- Presence of symptomatic musculoskeletal disorders affecting the lower limbs (LL) (relevant orthopedic surgery or leg length discrepancy > 1 cm), or other neurological conditions (stroke, neuropathies, etc.) that independently affect gait.
- Balance disorders due to other causes (vestibulopathy, severe orthostatic hypotension, etc.).
- Decompensated systemic diseases (cardiac disease, COPD, uncontrolled diabetes mellitus, etc.).
- Uncorrected visual impairments that may affect gait performance.
- Previous treatment with deep brain stimulation.
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
|---|
|
Parkinson Desease
Patients with Parkinson's disease recruited from the Parkinson's Association of Seville
|
|
Healthy Subjects
Patients with similar sociodemographic characteristics without neurological disorders
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
%MIVC
Tidsram: Baseline (Day 1)
|
It was calculated by expressing the Root Mean Square (RMS) value for each condition as a percentage of the Maximal Voluntary Contraction (MVC) obtained during the isometric test.
This approach ensures accurate quantification of neuromuscular effort, which is essential to minimize bias arising from anatomical and physiological differences between subjects.
|
Baseline (Day 1)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
CVM
Tidsram: Baseline (Day 1)
|
The Maximal Voluntary Contraction (MVC) was established as the reference value for neuromuscular activation capacity for each muscle (TA and GM).
This variable was obtained as the mean of three repetitions of maximal isometric activation lasting 6 seconds, allowing standardization of muscle responses to the dynamic efforts performed during gait.
|
Baseline (Day 1)
|
|
Ratio (GM/TA)
Tidsram: Baseline (Day 1)
|
It is calculated as the ratio of activation between the agonist and antagonist muscles during the gait cycle.
This index is used to assess muscle co-activation strategies and the mechanical efficiency of gait.
|
Baseline (Day 1)
|
Samarbetspartners och utredare
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Synukleinopatier
- Neurologiska manifestationer
- Hjärnsjukdomar
- Sjukdomar i centrala nervsystemet
- Sjukdomar i nervsystemet
- Neurodegenerativa sjukdomar
- Rörelsestörningar
- Parkinsons sjukdom
- Basala ganglia sjukdomar
- Patologiska tillstånd, tecken och symtom
- Tecken och symtom
- Parkinsons sjukdom
- Gångstörningar, neurologiska
Andra studie-ID-nummer
- SICEIA-2025-000444
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .